No Data
Shijiazhuang Yiling Pharmaceutical (002603.SZ): Withdrawn the clinical trial application for G201-Na capsule medication.
On January 7, Gelonghui reported that Shijiazhuang Yiling Pharmaceutical (002603.SZ) announced that, in accordance with the relevant policies for pharmaceutical approval and considering the progress of its research projects, the company has prudently decided to apply to the National Medical Products Administration to withdraw the clinical trial application for "G201-Na Capsules" regarding "Assisted Reproduction indications." Recently, the company received the Notice of Termination of Drug Registration Application approved and issued by the National Medical Products Administration. The G201-Na Capsule project is a Class I chemical new drug independently developed by the company with independent intellectual property rights. This product is a small molecule gonadotropin-releasing hormone (GnRH) receptor antagonist.
The seasonal influenza A has entered the epidemic period, and the sales of related Chinese Patent Medicine products have significantly increased.
① Recently, the positive rate of influenza virus has significantly increased, with over 99% being type A influenza. Market data shows a clear increase in the demand for various Traditional Chinese Medicine cold medicine products. ② Today, stock prices of several listed companies in the Traditional Chinese Medicine Industry, such as Shanxi Zhendong Pharmaceutical, Hainan Huluwa Pharmaceutical Group, and Zhongsheng Pharmaceutical, have reached the daily limit, with the Traditional Chinese Medicine Sector overall rising, and the Traditional Chinese Medicine 50 ETF increasing by 3.21%.
Does Shijiazhuang Yiling Pharmaceutical (SZSE:002603) Have A Healthy Balance Sheet?
Shijiazhuang Yiling Pharmaceutical (002603.SZ): The clinical trial registration application for the Traditional Chinese Medicine new drug "Lianhua Yuping Granules" has been approved.
Shijiazhuang Yiling Pharmaceutical (002603.SZ) announced that its wholly-owned subsidiary Peking Yiling Pharmaceutical Co., Ltd. ("Peking...
Yiling Pharmaceutical Unit Gets Nod to Market Simvastatin Tablets in US
Shenzhen Stock Exchange: Adjustment of the sample stocks for the Shenzhen component index, Chinext price index, and szse 100 price index.
On December 2, the Shenzhen Stock Exchange announced that according to the index compilation rules, the Shenzhen Stock Exchange and Shenzhen Securities Information Co., Ltd. decided to implement periodic adjustments to the Shenzhen Component Index, chinext price index, szse 100 price index, and other indexes on December 16, 2024.
Benign Growth For Shijiazhuang Yiling Pharmaceutical Co., Ltd. (SZSE:002603) Underpins Its Share Price
No Data
